Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Minipuberté de la petite enfance et moment du développement pubertaire à l'adolescence : un suivi de la cohorte de l'alimentation du nourrisson et du développement précoce (IFED)

Background:

Earlier puberty is associated with adverse health throughout a person s life. The average age when puberty begins has been declining over the past decades in girls, and may also be declining in boys. The reasons for this shift are unknown.

Objective:

To determine whether internal (physical, hormonal) or external (feeding, environment) factors during infancy affect growth and the timing of puberty.

Eligibility:

Mothers (or other parent/guardian) and their children who completed the Infant Feeding and Early Development (IFED) study.

Design:

Participants will complete all activities at home for this natural history study.

Participant mothers will fill out two 15-minute questionnaires:

  • One will be about themselves. They will answer questions about their body size in childhood, their puberty, and their pregnancies.
  • The other will be about their child. They will answer questions about their child s puberty and lifestyle.

Child participants will fill out a questionnaire about their body changes during puberty. This will take 10 minutes.

Participants will be sent an electronic scale and a measuring tape. They will measure the child s weight, height, and waist and hip circumference. These numbers can be submitted online or by phone or mail.

Participants will receive a kit for collecting urine samples. Child participants will collect urine in a cup upon waking 4 days in a row. A special filter card is dipped in the cup then hung to dry. The dried cards will be mailed back.

Participants will allow researchers to access their child s medical records.

Questionnaires and body measurements will be repeated after 6 and 12 months. Urine sample collection will be repeated after 12 months.

All questionnaires can be done either online, by mail, or by phone on request.

Aperçu de l'étude

Statut

Inscription sur invitation

Les conditions

Description détaillée

Study Description: Our overarching hypothesis is that endogenous and exogenous factors related to hypothalamic-pituitary-gonadal (HPG) axis activity during minipuberty of infancy are associated with childhood growth, the timing of pubertal development, and HPG axis activity in adolescence. To examine this hypothesis, we will conduct an observational follow-up study of children previously enrolled as infants in the Infant Feeding and Early Development (IFED) cohort. This follow-up study will be conducted remotely with data collection via email/online, mail and telephone by contractors at DLH, working on behalf of NIEHS.

Objectives: Primary Objective: To assess whether endogenous (e.g. hormone concentrations and size of hormone-sensitive organs) and exogenous (e.g. infant feeding method, exposure to endocrine disrupting chemicals) factors during minipuberty of infancy are related to a) growth, b) timing of pubertal development, and c) HPG axis activity in adolescence.

Endpoints: Primary Endpoints:

  1. Height, weight and body mass index (BMI)
  2. Onset of breast, pubic hair and/or genital development
  3. Urinary metabolites of reproductive hormones (e.g. gonadotropins and sex steroids)

Type d'étude

Observationnel

Inscription (Estimé)

566

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Maryland
      • Bethesda, Maryland, États-Unis, 20892
        • National Institute of Environmental Health Sciences (NIEHS)
    • North Carolina
      • Durham, North Carolina, États-Unis, 27703
        • Social & Scientific Systems

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

8 ans à 100 ans (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The eligible population includes 283 children (136 girls, 147 boys), and their mothers or other parent/guardian, who completed the original IFED study, conducted when the children where 0-9 months of age (2010-2014).

La description

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Completion of the original IFED study, defined as participants who did not withdraw from the study or were not withdrawn by the investigator prior to the end of original follow-up (up to 7 months in males and 9 months in females) and who provided at least the minimum number of blood samples (3 for boys, 4 for girls) across the original study period (N=283 eligible families).
  2. Ability of subject and mother to understand and the willingness to review informed assent and consent documents, respectively, and indicate agreement to participate.

EXCLUSION CRITERIA:

We will not exclude any participants that meet the inclusion criteria from participating in the study overall or in any of the study procedures. We will collect information, via maternal report and linked medical records, on relevant medical diagnoses and the use of medications that may affect hormone levels, growth, and pubertal development. We may exclude participants with reported conditions or medication use (listed below) from analyses of some study aims or in sensitivity analyses.

Diagnoses/conditions:

  • Central or peripheral precocious puberty
  • Delayed puberty
  • Growth hormone deficiency
  • Stunted or delayed growth
  • Idiopathic short stature
  • Hypopituitarism
  • Thyroid conditions, such as hyperthyroid, hypothyroid, Graves disease, Hashimoto's thyroiditis
  • Genetic conditions, such as Prader-Willi syndrome, Turner syndrome, and Noonan syndrome

Medications:

  • Gonadotropin-Releasing Hormone Agonists (e.g., leuprolide acetate (Lupron Depot), triptorelin (Triptodur), histrelin implant (Supprelin LA))
  • Hormone therapy (e.g., testosterone, estrogen)
  • Synthetic human growth hormone or IGF-1
  • Synthetic thyroid hormone (e.g., levothyroxine)
  • Anti-thyroid medications (e.g., methimazole, propylthiouracil) or radioactive iodine treatment

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
IFED-2

Children who participated in the IFED study as infants (2010-2014) and a parent/guardian will be enrolled in this follow-up study in childhood and followed for at least one year.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To assess whether growth, timing of pubertal development, and hypothalamic-pituitary-gonadal (HPG) axis activity in childhood and adolescence are related to endogenous and exogenous endocrine-related factors during minipuberty of infancy.
Délai: Various time points in childhood/adolescence (study enrollment, 6-month and 12-month follow-up visits currently planned). We anticipate that children will be 8-12 years of age at enrollment (2022) and followed prospectively.

1)Growth in height, weight and body mass index 2)Onset of pubic hair development, breast development (females), genital development (males) 3)Urinary concentrations of reproductive hormone metabolites (e.g., gonadotropins, estradiol, testosterone)

Various time points in childhood/adolescence (study enrollment, 6-month and 12-month follow-up visits currently planned). We anticipate that children will be 8-12 years of age at enrollment (2022) and followed prospectively.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Dale P Sandler, Ph.D., National Institute of Environmental Health Sciences (NIEHS)

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 octobre 2022

Achèvement primaire (Estimé)

1 mars 2027

Achèvement de l'étude (Estimé)

1 mars 2027

Dates d'inscription aux études

Première soumission

15 juillet 2022

Première soumission répondant aux critères de contrôle qualité

15 juillet 2022

Première publication (Réel)

18 juillet 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 septembre 2026

Dernière vérification

22 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 10000945
  • 000945-E

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

Individual participant data may be shared with other researchers upon request. Plans for sharing data if requested are included in the study protocol.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner